Molecular diagnosis of prostate cancer: Are we up to age?

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 259-275

  Bhavsar, Tapan ^a   McCue, Peter ^a   Birbe, Ruth ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACID PHOSPHATASE PROSTATE ISOENZYME; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 6; CAVEOLIN 1; CHROMOGRANIN A; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SYNDECAN 1; TISSUE KALLIKREIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN RECEPTOR 3;

APOPTOSIS; ARTICLE; ARTIFICIAL INTELLIGENCE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GLEASON SCORE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE MODIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEARNING ALGORITHM; LIPID METABOLISM; LYMPH NODE METASTASIS; MICROMETASTASIS; MOLECULAR DIAGNOSIS; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR GROWTH;

EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879436659     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.002     Document Type: Article

References (218)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics CA Cancer J Clin 55 2005 10 30
2. P. Boyle, and J. Ferlay Cancer incidence and mortality in Europe Ann Oncol 16 2005 481 488
3. S. Franceschi, and C. La Vecchia Cancer epidemiology in the elderly Crit Rev Oncol Hematol 39 2001 219 226
4. C.J. Ercole, P.H. Lange, and M. Mathisen Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer J Urol 138 1987 1181 1184
5. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level
6. W.K. Oh, M. Hurwitz, and A.V. D'Amico Neoplasms of the prostate D.W. Kufe, R.E. Pollock, RR Weichselbaum, Cancer medicine 2003 BC Decker Hamilton, Canada
7. T. Scholzen, and J. Gerdes The Ki-67 protein: from the known and the unknown J Cell Physiol 182 2000 311 322
8. B.L. Chang, S.D. Isaacs, and K.E. Wiley Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease Prostate 64 2005 356 361
9. J. Rubio, D. Ramos, and J.A. Lopez-Guerrero Immunohistochemical expression of Ki-67 antigen,COX-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens Eur Urol 48 2005 745 751
10. K. Revelos, C. Petraki, and A. Gregorakis p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer In Vivo 19 2005 911 920
11. A. Khatami, J. Hugosson, and W. Wang Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy Scand J Urol Nephrol 43 2009 12 18
12. D.M. Berney, A. Gopalan, and S. Kudahetti Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study Br J Cancer 100 2009 888 893
13. L.Y. Khor, K. Bae, and R. Paulus MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02 J Clin Oncol 27 2009 3177 3184
14. R. Bookstein, D. MacGrogan, S.G. Hilsenbeck, F. Sharkey, and D.C. Allred p53 is mutated in a subset of advanced-stage prostate cancers Cancer Res 53 1993 3369 3373
15. N.M. Navone, P. Troncoso, and L.L. Pisters p53 protein accumulation and gene mutation in the progression of human prostate carcinoma J Natl Cancer Inst 85 1993 1657 1669
16. J.J. Bauer, I.A. Sesterhenn, F.K. Mostofi, D.G. McLeod, S. Srivastava, and J.W. Moul Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer J Urol 156 1996 1511 1516
17. H.J. Stricker, J.K. Jay, M.D. Linden, P. Tamboli, and M.B. Amin Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53 Urology 47 1996 366 369
18. T. Visakorpi, O.P. Kallioniemi, A. Heikkinen, T. Koivula, and J. Isola Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation J Natl Cancer Inst 84 1992 883 887
19. I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H.I. Scher, and C. Cordon-Cardo Inactivation of the p53 pathway in prostate cancer: impact on tumor progression Clin Cancer Res 5 1999 2082 2088
20. D.J. Grignon, R. Caplan, and F.H. Sarkar p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610 J Natl Cancer Inst 89 1997 158 165
21. M.A. Kuczyk, J. Serth, and C. Bokemeyer The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy Eur J Cancer 34 1998 679 686
22. T. Inoue, T. Segawa, and T. Shiraishi Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population Urology 66 2005 332 337
23. X.B. Shi, R. Gandour-Edwards, L.A. Beckett, A.D. Deitch, and R.W. Vere White A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value BJU Int 94 2004 996 1002
24. H.B. Heidenberg, I.A. Sesterhenn, and J.P. Gaddipati Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer J Urol 154 1995 414 421
25. A.J. Raffo, H. Perlman, M.W. Chen, M.L. Day, J.S. Streitman, and R. Buttyan Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 55 1995 4438 4445
26. I. Apakama, M.C. Robinson, and N.M. Walter bcl-2 overexpression combined with p53 protein accumulation correlates with hormone refractory prostate cancer Br J Cancer 74 1996 1258 1262
27. R. Kuefer, S. Varambally, and M. Zhou Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation Am J Pathol 161 2002 841 848
28. S. Zha, S. Ferdinandusse, and S. Denis Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer Cancer Res 63 2003 7365 7376
29. Z. Jiang, C.L. Wu, and B.A. Woda Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker Histopathology 45 2004 218 225
30. Z. Jiang, B.A. Woda, C.L. Wu, and X.J. Yang Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S) Am J Clin Pathol 122 2004 275 289
31. D. Hessels, G.W. Verhaegh, J.A. Schalken, and J.A. Witjes Applicability of biomarkers in the early diagnosis of prostate cancer Expert Rev Mol Diagn 4 2004 513 526
32. M.A. Rubin, M. Zhou, and S.M. Dhanasekaran alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer JAMA 287 2002 1662 1670
33. R.L. Fleshman, and G.T. MacLennan Immunohistochemical markers in the diagnosis of prostate cancer J Urol 173 2005 1759
34. Z. Jiang, C. Li, A. Fischer, K. Dresser, and B.A. Woda Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens Am J Clin Pathol 123 2005 231 236
35. Z. Jiang, C.L. Wu, and B.A. Woda P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy Am J Surg Pathol 26 2002 1169 1174
36. P.J. Zielie, J.A. Mobley, and R.G. Ebb A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions J Urol 172 2004 1130 1133
37. C.G. Rogers, G. Yan, and S. Zha Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein J Urol 172 2004 1501 1503
38. A.K. Gregorakis, E.H. Holmes, and G.P. Murphy Prostate-specific membrane antigen: current and future utility Semin Urol Oncol 16 1998 2 12
39. G.P. Murphy, G.M. Kenny, and H. Ragde Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer Urology 51 1998 89 97
40. G.P. Murphy, R.J. Barren, and S.J. Erickson Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen Cancer 78 1996 809 818
41. C. Marchal, M. Redondo, and M. Padilla Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia Histol Histopathol 19 2004 715 718
42. J.Q. Ren, Z.Q. Chen, and L. Zheng Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma [in Chinese] Zhonghua Zhong Liu Za Zhi 26 2004 735 738
43. G. Murphy, H. Ragde, and G. Kenny Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients Anticancer Res 15 1995 1473 1479
44. T. Xu, X. Chen, and X.F. Wang Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications Beijing Da Xue Xue Bao 36 2004 164 168
45. S.L. Su, A.L. Boynton, and E.H. Holmes Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction Semin Surg Oncol 18 2000 17 28
46. A.D. Lopes, W.L. Davis, and M.J. Rosenstraus Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5 Cancer Res 50 1990 6423 6429
47. S.Y. Cho, K. Choi, and J.H. Jeon Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer Exp Mol Med 42 2010 310 318
48. A. Angelucci, C. Festuccia, and G.L. Gravina Osteopontin enhances the cell proliferation induced bythe epidermal growth factor in human prostate cancer cells Prostate 59 2004 157 166
49. B.W. Robertson, L. Bonsal, and M.A. Chellaiah Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells Mol Cancer 9 2010 260 270
50. G.F. Weber, G.S. Lett, and N.C. Haubein Categorical meta-analysis of osteopontin as a clinical cancer marker Oncol Rep 25 2011 433 441
51. A. Angelucci, C. Festuccia, G. D'Andrea, and A. Teti Bologna M. Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators Biol Chem 383 2002 229 234
52. A.C. Khodavirdi, Z. Song, and S. Yang Increased expression of osteopontin contributes to the progression of prostate cancer Cancer Res 66 2006 883 888
53. W. Liu, J. Gong, and J. Hu Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason Score Urology 77 1006 2011 e1 e7
54. A. Ramankulov, M. Lein, G. Kristiansen, S.A. Loening, and K. Jung Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer Prostate 67 2007 330 340
55. Y. Zhang, S.S. Forootan, and L. Kamalian Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression Int J Oncol 38 2011 1083 1091
56. F.C. Hamdy, P. Autzen, M.C. Robinson, C.H. Horne, D.E. Neal, and C.N. Robson Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue Cancer Res 57 1997 4427 4431
57. P. Autzen, C.N. Robson, and A. Bjartell Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies Br J Cancer 78 1998 1219 1223
58. H. Tamada, R. Kitazawa, K. Gohji, and S. Kitazawa Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer J Bone Miner Res 16 2001 487 496
59. G. De Pinieux, T. Flam, and M. Zerbib Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases J Urol 166 2001 1924 1930
60. X. Mao, Y. Yu, and L.K. Boyd Distinct genomic alterations in prostate cancers in Chinese and western populations suggest alternative pathways of prostate carcinogenesis Cancer Res 70 2010 5207 5212
61. J. Domingo-Domenech, B. Mellado, and B. Ferrer Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse Br J Cancer 93 2005 1285 1294
62. S.J. Jaraj, M. Augsten, and L. Häggarth GAD1 is a biomarker for benign and malignant prostatic tissue Scand J Urol Nephrol 45 2011 39 45
63. L. Haggarth, F.C. Hagglo, and S.J. Jaraj Diagnostic biomarkers of prostate cancer Scand J Urol Nephrol 45 2011 60 67
64. S.J. Freedland, D.B. Seligson, and A.Y. Liu Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer Prostate 55 2003 71 80
65. T. Zellweger, C. Ninck, and M. Mirlacher Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer Prostate 55 2003 20 29
66. W. Xin, D.R. Rhodes, C. Ingold, A.M. Chinnaiyan, and M.A. Rubin Dysregulation of the annexin family protein family is associated with prostate cancer progression Am J Pathol 162 2003 255 261
67. L. Udby, J.B. Cowland, A.H. Johnsen, O.E. Sorensen, N. Borregaard, and L. Kjeldsen An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human neutrophils, plasma, and exocrine secretions J Immunol Methods 263 2002 43 55
68. C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S.A. Loening Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer Cancer Epidemiol Biomarkers Prev 9 2000 1133 1147
69. G.G. Klee, M.K. Goodmanson, and S.J. Jacobsen Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2 Clin Chem 45 1999 800 806
70. A. Haese, V. Vaisanen, and J.A. Finlay Standardization of two immunoassays for human glandular kallikrein 2 Clin Chem 49 2003 601 610
71. V. Vaisanen, S. Eriksson, K.K. Ivaska, H. Lilja, M. Nurmi, and K. Pettersson Development of sensitive immunoassays for free and total human glandular kallikrein 2 Clin Chem 50 2004 1607 1617
72. J.M. Brown, R.L. Vessella, P.J. Kostenuik, C.R. Dunstan, P.H. Lange, and E. Corey Serum osteoprotegerin levels are increased in patients with advanced prostate cancer Clin Cancer Res 7 2001 2977 2983
73. C.L. Eaton, J.M. Wells, I. Holen, P.I. Croucher, and F.C. Hamdy Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer Prostate 59 2004 304 310
74. L.J. Deftos, and P.A. Abrahamsson Granins and prostate cancer Urology 51 1998 141 145
75. S. Fracalanza, T. Prayer-Galetti, and F. Pinto Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination Urol Int 75 2005 57 61
76. P. Chapdelaine, G. Paradis, and R.R. Tremblay High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen FEBS Lett 236 1988 205 208
77. L.J. Schedlich, B.H. Bennetts, and B.J. Morris Primary structure of a human glandular kallikrein gene DNA 6 1987 429 437
78. R.K. Nam, E.P. Diamandis, and A. Toi Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen J Clin Oncol 18 2000 1036 1042
79. C. Becker, T. Piironen, and K. Pettersson Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 55 2000 694 699
80. D.J. George, S. Halabi, and T.F. Shepard The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone refractory prostate cancer: results from Cancer and Leukemia Group B 9480 Clin Cancer Res 11 2005 1815 1820
81. B. Barre, S. Avril, and O. Coqueret Opposite regulation of myc and p21waf1 transcription by STAT3 proteins J Biol Chem 278 2003 2990 2996
82. S.F. Shariat, M.W. Kattan, and E. Traxel Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression Clin Cancer Res 10 2004 1992 1999
83. D.E. Drachenberg, A.A. Elgamal, and R. Rowbotham Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer Prostate 41 1999 127 133
84. V. Michalaki, K. Syrigos, and P. Charles Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
85. Y. Furuya, R. Nishio, and A. Junicho Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer Int Urol Nephrol 37 2005 69 71
86. S. Lehrer, E.J. Diamond, and B. Mamkine Serum interleukin-8 is elevated in men with prostate cancer and bone metastases Technol Cancer Res Treat 3 2004 411
87. M.W. Kattan, S.F. Shariat, and B. Andrews The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 21 2003 3573 3579
88. D. Di Vizio, M. Morello, and F. Sotgia An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation Cell Cycle 8 2009 2420 2424
89. J. Musiał, S. Sporny, and A. Nowicki Prognostic significance of E-cadherin and Ezrin immunohistochemical expression in prostate cancer Pol J Pathol 58 2007 235 243
90. G. Di Lorenzo, G. Tortora, and F.P. D'Armiento Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res 8 2002 3438 3444
91. J.L. Duque, K.R. Loughlin, R.M. Adam, P.W. Kantoff, D. Zurakowski, and M.R. Freeman Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer Urology 54 1999 523 527
92. D.J. George, S. Halabi, and T.F. Shepard Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480 Clin Cancer Res 7 2001 1932 1936
93. Y.M. El-Gohary, J.F. Silverman, and P.R. Olson Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma Am J Clin Pathol 127 2007 572 579
94. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 1993 401 409
95. J.C. Miller, H. Zhou, and J. Kweke Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers Proteomics 3 2003 56 63
96. C. Kumar-Sinha, S.A. Tomlins, and A.M. Chinnaiyan Recurrent gene fusions in prostate cancer Nat Rev Cancer 8 2008 497 511
97. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
98. J. Gerdes, U. Schwab, and H. Lemke Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 1983 13 20
99. J.M. Mosquera, R. Mehra, and M.M. Regan Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States Clin Cancer Res 15 2009 4706 4711
100. D. Hessels, F.P. Smit, and G.W. Verhaegh Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 2007 5103
101. M. Yoshimoto, A.M. Joshua, and I.W. Cunha Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome Mod Pathol 21 2008 1451 1460
102. K. Mwamukonda, Y. Chen, and L. Ravindranath Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status Prostate Cancer Prostatic Dis 13 2010 47-5
103. Y. Fradet Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen Curr Opin Urol 19 2009 243 246
104. D.L. Cao, D.W. Ye, and H.L. Zhang A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer Prostate 71 2010 700
105. J. Nilsson, J. Skog, and A. Nordstrand Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer Br J Cancer 100 2009 1603 1607
106. P.J. Mitchell, J. Welton, J. Staffurth, and J. Court Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 12 2009 4
107. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
108. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
109. G. Ploussard, and A. de la Taille Urine biomarkers in prostate cancer Nat Rev Urol 7 2010 101 109
110. D. Hessels, J.M. Klein Gunnewiek, and I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 15
111. M. Tinzl, M. Marberger, and S. Horvath Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer Eur Urol 46 2004 182 186
112. Y. Fradet, F. Saad, and A. Aprikian uPM3, a new molecular urine test for the detection of prostate cancer Urology 64 2004 311 315
113. J. Groskopf, S.M. Aubin, and I.L. Deras Aptima PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095
114. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
115. J. Ruiz-Aragon, and S. Marquez-Pelaez Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis Actas Urol Esp 34 2010 346 355
116. M. Zhang, E.H. Hammond, and Y. Suzuki Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610 Int J Radiat Oncol Biol Phys 73 2009 1033 1042
117. H. Wang, X. Xi, X. Kong, G. Huang, and G. Ge The expression and significance of survivin mRNA in urinary bladder carcinomas J Cancer Res Clin Oncol 130 2004 487 490
118. F.H. Meid, C.M. Gygi, H.J. Leisinger, F.T. Bosman, and J. Benhattar The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage J Urol 165 2001 1802 1805
119. G.I. Botchkina, R.H. Kim, I.L. Botchkina, A. Kirshenbaum, Z. Frischer, and H.L. Adler Noninvasive detection of prostate cancer by D. Hessels et al. / EAU Update Series 3 (2005). 200-213 211 quantitative analysis of telomerase activity Clin Cancer Res 11 2005 3243 3249
120. L.M. Hutchinson, E.L. Chang, and C.M. Becker Development of a sensitive and specific enzyme linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer Clin Biochem 38 2005 558 571
121. L.M. Hutchinson, E.L. Chang, and C.M. Becker Use of thymosin beta15 as a urinary biomarker in human prostate cancer Prostate 16 2005 116 127
122. S.M. Dhanasekaran, T.R. Barrette, and D. Ghosh Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
123. J. Luo, D.J. Duggan, and Y. Chen Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling Cancer Res 61 2001 4683 4688
124. J.A. Magee, T. Araki, and S. Patil Expression profiling reveals hepsin overexpression in prostate cancer Cancer Res 61 2001 5692 5696
125. D.R. Rhodes, T.R. Barrette, and M.A. Rubin Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer Cancer Res 62 2002 4427 4433
126. T.A. Stamey, J.A. Warrington, and M.C. Caldwell Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia J Urol 166 2001 2171 2177
127. J.B. Welsh, L.M. Sapinoso, and A.I. Su Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer Cancer Res 61 2001 5974 5978
128. M. Tanaka, T. Tanaka, and S. Matsuzaki Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers Med Sci Monit 9 2003 MT61 MT68
129. T.J. Dudderidge, J.D. Kelly, and A. Wollenschlaeger Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments Br J Cancer 103 2010 701 707
130. C. Jeronimo, S. Nomoto, and O.L. Caballero Mitochondrial mutations in early stage prostate cancer and bodily fluids Oncogene 20 2001 5195 5198
131. T. Richardson, W. McCanse, and G.P. Casale Tissue-based quantification of 8-hydroxy-2'-deoxyguanosine in human prostate biopsies using quantitative fluorescence imaging analysis Urology 74 2009 1174 1179
132. M.E. Lombardo, and P.B. Hudson Preliminary evaluation of 5a-reductase type 2 in urine as potential marker for prostate disease Steroids 62 1997 682 685
133. A.W. Partin, R.H. Getzenberg, and M.J. CarMichael Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer Cancer Res 53 1993 744 746
134. R. Dhir, B. Vietmeier, and J. Arlotti Early identification of individuals with prostate cancer in negative biopsies J Urol 171 2004 1419 1423
135. H. Uetsuki, H. Tsunemori, and R. Taoka Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate J Urol 174 2005 514 518
136. B. Paul, R. Dhir, and D. Landsittel Detection of prostate cancer with a blood-based assay for early prostate cancer antigen Cancer Res 65 2005 4097 4100
137. K.R. Han, D.B. Seligson, and X. Liu Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer J Urol 171 2004 1117 1121
138. J.S. Lam, J. Yamashiro, and I.P. Shintaku Prostate stem cell antigen is overexpressed in prostate cancer metastases Clin Cancer Res 11 2005 2591 2596
139. Z. Zhigang, and S. Wenlv Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: Implications for prostate carcinogenesis and progression of prostate cancer Jpn J Clin Oncol 34 2004 414 419
140. Z. Gu, G. Thomas, and J. Yamashiro Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer Oncogene 19 2000 1288 1296
141. N. Hara, T. Kasahara, and T. Kawasaki Reverse transcription polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer Clin Cancer Res 8 2002 1794 1799
142. W.A. Schulz, and J. Hatina Epigenetics of prostate cancer: beyond DNA methylation J Cell Mol Med 10 2006 100 125
143. L.C. Li, P.R. Carroll, and R. Dahiya Epigenetic changes in prostate cancer: implication for diagnosis and treatment J Natl Cancer Inst 97 2005 103 115
144. W. Lee, R.A. Morton, J.L. Epstein, J.D. Brooks, P.A. Campbell, and G.S. Bova Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis Proc Natl Acad Sci U S A. 91 1994 11733 11737
145. W.H. Lee, W.B. Isaacs, G.S. Bova, and W.G.C.G. Nelson island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker Cancer Epidemiol Biomark Prev 6 1997 433 450
146. M. Esteller, P.G. Corn, J.M. Urena, E. Gabrielson, S.B. Baylin, and J.G. Herman Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia Cancer Res 58 1999 4515 4518
147. S. Bernardini, R. Miano, and R. Iori Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Clin Chim Acta 350 2004 181 188
148. C. Jeronimo, H. Usadel, and R. Henrique Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma J Natl Cancer Inst 93 2001 1747 1752
149. D.C. Chu, C.K. Chuang, and J.B. Fu The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma J Urol 167 2002 1854 1858
150. J.D. Brooks, M. Weinstein, and X. Lin CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia Cancer Epidemiol Biomark Prev 7 1998 531 536
151. P. Cairns, M. Esteller, and J.G. Herman Molecular detection of prostate cancer in urine by GSTP1 hypermethylation Clin Cancer Res 7 2001 2727 2730
152. S.V. Harden, H. Sanderson, and S.N. Goodman Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies J Natl Cancer Inst 95 2003 1634
153. S. Yegnasubramanian, J. Kowalski, and M.L. Gonzalgo Hypermethylation of CpG islands in primary and metastatic human prostate cancer Cancer Res 64 2004 1975 1986
154. M. Roupret, M. Hupertan, and V. Yates, DR Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage Clin Cancer Res 13 2007 1720 1725
155. G.H. Kang, S. Lee, H.J. Lee, and K.S. Hwang Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia J Pathol 202 2004 233
156. S. Yegnasubramanian, M.C. Haffner, and Y. Zhang DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity Cancer Res 68 2008 8954 8967
157. A.R. Brothman, G. Swanson, and T.M. Maxwell Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 156 2005 31 36
158. S. Santourlidis, A. Florl, R. Ackermann, H.C. Wirtz, and W.A. Schulz High frequency of alterations in DNA methylation in adenocarcinoma of the prostate Prostate 39 1999 166 174
159. W.A. Schulz, J.P. Elo, and A.R. Florl Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma Genes Chromosomes Cancer 35 2002 58 65
160. M. Neumaier, A. Braun, and C. Wagener Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics International Federation of Clinical Chemistry Scientific Division Committee on Molecular Biology Techniques. Clin Chem 44 1998 12 26
161. D.R. Rhodes, M.G. Sanda, A.P. Otte, A.M. Chinnaiyan, and M.A. Rubin Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J Natl Cancer Inst 95 2003 661 668
162. M.J. Hoffmann, R. Engers, A.R. Florl, A.P. Otte, M. Muller, and W.A. Schulz Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer Cancer Biol Ther 6 2007 1403 1412
163. S. Varambally, S.M. Dhanasekaran, and M. Zhou The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
164. G.J. van Leenders, D. Dukers, and D. Hessels Polycombgroup oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features Eur Urol 52 2007 455 463
165. D.B. Seligson, S. Horvath, and T. Shi Global histone modification patterns predict risk of prostate cancer recurrence Nature 435 2005 1262 1266
166. U. Deligezer, F. Yaman, and E. Darendeliler Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease Clin Chim Acta 411 2010 1452 1456
167. J. Lu, G. Getz, and E.A. Miska MicroRNA expression profiles classify human cancers Nature 435 2005 834 838
168. P.S. Mitchell, R.K. Parkin, and E.M. Kroh Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 105 2008 10513 10518
169. A. Schaefer, M. Jung, and H.J. Mollenkopf Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma Int J Cancer 126 2010 1166 1176
170. J.C. Brase, M. Johannes, and T. Schlomm Circulating miRNAs are correlated with tumor progression in prostate cancer Int J Cancer J 128 2011 608 616
171. A.W. Hsing, and A.P. Chokkalingam Prostate cancer epidemiology Front Biosci 11 2006 1388 1413
172. D.K. Vanaja, K.V. Ballman, and B.W. Morlan PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer Clin Cancer Res 12 2006 1128 1136
173. H. Chen, S. Toyooka, and A.F. Gazdar Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines J Biol Chem 278 2003 3121 3130
174. D. Duggan, S.L. Zheng, and M. Knowlton Two genome-wide association studies of aggressive prostate cancer implicate put ative prostate tumor suppressor gene DAB2IP J Natl Cancer Inst 99 2007 1836 1844
175. S. Wilson, B. Greer, and J. Hooper The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells Biochem J 388 2005 967 972
176. P.C. Black, G.J. Mize, and P. Karlin Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer Prostate 67 2007 743 756
177. A.L. Omara-Opyene, J. Qiu, G.V. Shah, and K.A. Iczkowski Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18 Lab Invest 84 2004 894 907
178. S. Aaltomaa, P. Lipponen, J. Viitanen, J.P. Kankkunen, M. Ala-Opas, and V.M. Kosma Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy Eur Urol 38 2000 555 562
179. S. Aaltomaa, M. Eskelinen, and P. Lipponen Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival Prostate 38 1999 175 182
180. B.V. Kallakury, C.E. Sheehan, R.A. Ambros, H.A. Fisher, R.P. Kaufman Jr, and J.S. Ross The prognostic significance of p34cdc2 and cyclinD1 protein expression in prostate adenocarcinoma Cancer 80 1997 753 763
181. T.T. Nguyen, C.T. Nguyen, F.A. Gonzales, P.W. Nichols, M.C. Yu, and P.A. Jones Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers Prostate 43 2000 233 242
182. L. Bubendorf, J. Kononen, and P. Koivisto Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 1999 803 806
183. R.B. Jenkins, J. Qian, M.M. Lieber, and D.G. Bostwick Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization Cancer Res 57 1997 524 531
184. D. Bernard, A. Pourtier-Manzanedo, J. Gil, and D.H. Beach Myc confers androgen-independent prostate cancer cell growth J Clin Invest 112 2003 1724 1731
185. K. Sato, J. Qian, and J.M. Slezak Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma J Natl Cancer Inst 91 1999 1574 1580
186. D.F. Jarrard, J. Modder, and P. Fadden Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer Cancer Lett 185 2002 191 199
187. A. Chakravarti, K. Heydon, and C.L. Wu Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10 J Clin Oncol 21 2003 3328 3334
188. L.A. Maddison, B.W. Sutherland, R.J. Barrios, and N.M. Greenberg Conditional deletion of Rb causes early stage prostate cancer Cancer Res 64 2004 6018 6025
189. D. Theodorescu, S.R. Broder, J.C. Boyd, S.E. Mills, and H.F. Frierson Jr p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate J Urol 158 1997 131 137
190. A. Prtilo, F.S. Leach, and R. Markwalder Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer J Urol 174 2005 1814 1818
191. A. Velasco, P.S. Albert, H. Rosenberg, C. Martinez, and F.S. Leach Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer Cancer Biol Ther 1 2002 362 367
192. I. Fenic, F. Franke, K. Failing, K. Steger, and J. Woenckhaus Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression J Pathol 203 2004 559 566
193. A. Grimberg Mechanisms by which IGF-I may promote cancer Cancer Biol Ther 2 2003 630 635
194. A.G. Renehan, M. Zwahlen, C. Minder, S.T. O'Dwyer, S.M. Shalet, and M. Egger Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 2004 1346 1353
195. G.H. Xiao, M. Jeffers, A. Bellacosa, Y. Mitsuuchi, G.F. Vande Woude, and J.R. Testa Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways Proc Natl Acad Sci USA 98 2001 247 252
196. N.G. Dolloff, S.S. Shulby, and A.V. Nelson Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor Oncogene 24 2005 6848 6854
197. S. Shukla, G.T. MacLennan, and P. Fu Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression Neoplasia 6 2004 390 400
198. C.D. Chen, and C.L. Sawyers NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer Mol Cell Biol 22 2002 2862 2870
199. L. Lessard, L.R. Begin, M.E. Gleave, A.M. Mes-Masson, and F. Saad Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study Br J Cancer 93 2005 1019 1023
200. G. Zhang, H. Zhang, and Q. Wang Suppression of human prostate tumor growth by a unique prostatespecific monoclonal antibody F77 targeting a glycolipid marker Proc Natl Acad Sci U S A 107 2010 732 737
201. N. Ozaki, M. Ohmuraya, and M. Hirota Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor Mol Cancer Res 7 2009 1572 1581
202. A.P. Khan, L.M. Poisson, and V.B. Bhat Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer Mol Cell Proteomics 9 2010 298
203. A. Sreekumar, L.M. Poisson, and T.M. Rajendiran Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 457 2009 910
204. P.S. Nelson, D. Han, and Y. Rochon Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics Electrophoresis 21 2000 1823 1831
205. K.L. Meehan, J.W. Holland, and H.J. Dawkins Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer Prostate 50 2002 54 56
206. Y. Zheng, Y. Xu, and B. Ye Prostate carcinoma tissue proteomics for biomarker discovery Cancer 98 2003 2576 2582
207. I. Rehman, A.R. Azzouzi, and J.W. Catto Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study Urology 64 2004 1238 1243
208. P.K. Grover, and M.I. Resnick High resolution two-dimensional electrophoretic analysis of urinary proteins of patients with prostatic cancer Electrophoresis 18 1997 814 818
209. E.F. Petricoin III, D.K. Ornstein, and C.P. Paweletz Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 94 2002 1576 1578
210. Y. Qu, B.L. Adam, and Y. Yasui Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients Clin Chem 48 2002 1835 1843
211. H. Lexander, C. Palmberg, and U. Hellman Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer Proteomics 6 2006 4370 4380
212. G. Sardana, K. Jung, C. Stephan, and E.P. Diamandis Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers J Proteome Res 2008
213. T. Rabilloud Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains Proteomics 2 2002 3 10
214. R.L. Moritz, H. Ji, and F. Schutz A proteome strategy for fractionating proteins and peptides using continuous free-flow electrophoresis coupled off-line to reversed-phase high-performance liquid chromatography Anal Chem 76 2004 4811 4824
215. Y.W. Lam, J.A. Mobley, and J.E. Evans Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer Proteomics 5 2005 2927 2938
216. G. Malik, M.D. Ward, and S.K. Gupta Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer Clin Cancer Res 11 2005 1073 1085
217. L. Le, K. Chi, and S. Tyldesley Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions Clin Chem 51 2005 695 707
218. S. Qin, A.S. Ferdinand, and J.P. Richie Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins Proteomics 5 2005 3183 3192